DUPIXENT improved
asthma control in
patients aged 12+ years,
as measured by ACQ-51,a,b
of patients experienced
with DUPIXENT 200 mg Q2W +
SOC vs 67% with placebo +
SOC (OR: 1.46
[95% CI: 0.90,
2.35]) (baseline blood EOS
≥300 cells/μL, QUEST)
- 71% of patients improved their asthma control with DUPIXENT 300 mg Q2W + SOC vs 64% with placebo + SOC (OR:
1.39 [95% CI: 0.88, 2.19]) (baseline blood EOS ≥300 cells/µL, QUEST)
ACQ-5: Asthma Control Questionnaire, 5-item version, a patient-reported measure of asthma control. Higher scores indicate less
asthma control; a global score is calculated ranging from 0 to 6. The minimum clinically important difference is 0.5.1
DUPIXENT improved quality of life in patients aged 12+ years,
as measured by AQLQ(S)1,a,b
of patients experienced an
with DUPIXENT 200 mg Q2W +
SOC vs 55% with placebo +
SOC (OR:
2.02 [95% CI: 1.24,
3.32]) (baseline blood EOS
≥300 cells/μL, QUEST)
- 65% of patients experienced an improved quality of life with DUPIXENT 300 mg Q2W + SOC vs 55% with placebo + SOC
(OR: 1.79 [95% CI: 1.13, 2.85]) (baseline blood EOS ≥300 cells/µL, QUEST)
aResponder rates at Week 52 in QUEST were assessed as secondary endpoints and defined as an improvement in score of 0.5 or more (scale ranged from 0 to 6 for ACQ-5 and 1 to 7 for AQLQ[S]).1
bACQ-5 and AQLQ(S) were assessed as secondary endpoints but were ordered after the point at which the hierarchical break occurred.2
AQLQ(S): Asthma Quality of Life Questionnaire, Standardized Version, a patient-reported measure of asthma-related quality of life. Higher scores indicate better quality of life; a global score is calculated ranging from 1 to 7. The minimum clinically important difference is 0.5.1
EOS, eosinophils; OR, odds ratio; Q2W, once every 2 weeks; QoL, quality of life; SOC, standard of care.